Medical News

RSS

Ultrasound can predict high risk of stroke in patients with asymptomatic carotid stenosis

A new study shows that a simple ultrasound test may help to identify people at high risk of stroke who have a condition called asymptomatic carotid stenosis, a narrowing of the carotid artery found in the neck, in which few or no symptoms are present.

18 Aug 2011

CEL-SCI receives Chinese patent for Multikine cancer drug

CEL-SCI Corporation today announced that the Chinese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine.

18 Aug 2011

New research: Sniffer dogs can reliably identify lung cancer

Sniffer dogs could be used for the early detection of lung cancer, according to new research published in the European Respiratory Journal.

18 Aug 2011

Paladin to acquire Labopharm

Paladin Labs Inc. and Labopharm Inc. announced today that they have entered into a definitive agreement pursuant to which Paladin will acquire all of the issued and outstanding common shares of Labopharm at a price of $0.2857 per share in cash, which represents a premium of 57.4% over the volume-weighted average price of Labopharm's shares of $0.1815 for the 30 trading days prior to this announcement.

18 Aug 2011

Syndax receives European patent allowance for entinostat to treat metastatic breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the European Patent Office for the patent application titled "N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL) - METHOXYCARBONYL - AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

18 Aug 2011

Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma

Allos Therapeutics, Inc. today announced the enrollment of the first patient in a Phase 3 randomized clinical trial (PDX-017) evaluating FOLOTYN in patients with previously undiagnosed peripheral T-cell lymphoma.

18 Aug 2011

Sepracor Pharmaceuticals changes company name to Sunovion

Sunovion Pharmaceuticals Canada Inc., formerly Sepracor Pharmaceuticals, Inc., announced today that it has formally changed its name.

18 Aug 2011

Roche receives FDA approval for Zelboraf to treat BRAF mutation-positive metastatic melanoma

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as determined by an FDA-approved test.

18 Aug 2011

Roundup: Rx discounts for Medicaid programs are increasing; deadline extended for Mich. Medigap verifications

Governors have complained repeatedly in recent months that spiraling Medicaid costs are crushing their budgets. But there's good news on at least one line item in the $370 billion program — prescription drug discounts are getting more generous. According to a new report from the Inspector General of the U.S. Health and Human Services Department, discounts under the federal-state Medicaid program have been growing since 2006, adding up to a 45 percent rebate for most brand name drugs by 2009.

18 Aug 2011

Radioiodine being overused in thyroid cancer: Study

According to the latest research the use of radioactive iodine to treat thyroid cancer increased 40 percent from 1990 to 2008 even though the risks may outweigh the benefits for some patients, particularly those with early-stage tumors.

17 Aug 2011

New gout drug may help severely affected: Study

A new drug for gout could help very sick gout patients who don't get better with usual treatment, according to a new study. The research was designed and funded by the pharmaceutical company Savient, which markets the drug, called Krystexxa (pegloticase).

17 Aug 2011

Autism risk in siblings of autistic children is higher: Study

A new study reveals that parents with an autistic child have a 19% increased chance of getting another one with a similar disorder. Experts said the study, published Monday in the journal Pediatrics, is the most comprehensive of its kind and should be used to counsel families.

17 Aug 2011

Inherited genetic links to prostate cancer discovered

Researchers from the U.S. and Sweden have linked five inherited genetic mutations to the development of a particularly aggressive and deadly form of prostate cancer. They suggest that these findings could someday lead to development of an easy-to-administer blood test to screen for such mutations to help physicians assess the long-term risk faced by newly diagnosed prostate cancer patients.

17 Aug 2011

Harmless bacteria re-engineered to fight a deadly strain

Scientists in Singapore have re-engineered a harmless strain of bacteria to fight another common, drug-resistant microbe that spreads in hospitals and is deadly to patients with weak immune systems.

17 Aug 2011

Just 15 minutes of exercise per day prolongs life

Taiwanese researchers reported Monday in the journal The Lancet that exercising for just 15 minutes most days of the week appears to provide health benefits by prolonging life.

17 Aug 2011

Addiction – a brain disorder say experts

According to the American Society of Addiction Medicine, addiction is a chronic brain disorder like any other chronic brain disease such as obsessive-compulsive disorder and body dysmorphic disorder. Neurological abnormalities like disruptions in neurotransmission and the reward system drive addiction, the group said in a statement.

17 Aug 2011

Zelboraf receives FDA approval for treatment of metastatic melanoma

The U.S. Food and Drug Administration today approved Zelboraf (vemurafenib), a drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.

17 Aug 2011

First Edition: August 17, 2011

In today's headlines, a report about how the timing of the Supreme Court's health law review is in play -- will it happen before or after the 2012 election?

17 Aug 2011

FDA accepts Protalix taliglucerase alfa NDA resubmission for review

Protalix BioTherapeutics, Inc., announced today that the U.S. Food & Drug Administration (FDA) has accepted for review the resubmission of the taliglucerase alfa New Drug Application (NDA) following the Company's receipt of a Complete Response Letter (CRL) in February 2011.

17 Aug 2011

Centrify closes Series D round of financing

Centrify Corporation, the leading provider of security and compliance solutions that centrally control, secure and audit both on-premise and cloud-based systems and applications, today announced that it has closed its Series D round of financing.

17 Aug 2011